Evaluation of Posaconazole Therapeutic Drug Monitoring for Antifungal Prophylaxis in Hematology Patients at a Tertiary Referral Center
PCZ levels remain below target for nearly one-half of PCZ courses. Regular TDM during the first 14 days is critical, and patients with subtherapeutic levels at D7 should be prioritized for further close monitoring. A stepwise approach to pharmacist-led TDM-guided dose changes that follows a dosing guideline can improve target attainment for PCZ.
Authors
- Sue J. Lee (ORCID: https://orcid.org/0000-0002-8409-4248)
- Rekha Pai Mangalore (ORCID: https://orcid.org/0000-0002-8447-6836)
- Aadith Ashok (ORCID: https://orcid.org/0000-0002-6107-4113)
- Shevon Fernando
- John Coutsouvelis (ORCID: https://orcid.org/0000-0001-9788-6650)
- C. Orla Morrissey (ORCID: https://orcid.org/0000-0002-9970-9575)
Institutions
- Alfred Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Therapeutic Drug Monitoring
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1097/ftd.0000000000001425
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.00